Hiroki Hara Selected Research

Hiroki Hara Research Topics

Disease

45	Neoplasms (Cancer) 02/2024 - 09/2008
29	Stomach Neoplasms (Stomach Cancer) 01/2024 - 09/2008
24	Colorectal Neoplasms (Colorectal Cancer) 02/2024 - 12/2014
23	Esophageal Squamous Cell Carcinoma 05/2024 - 11/2013
12	Disease Progression 01/2024 - 02/2014
10	Esophageal Neoplasms (Esophageal Cancer) 04/2024 - 01/2019
10	Neoplasm Metastasis (Metastasis) 09/2023 - 11/2015
9	Adenocarcinoma 08/2023 - 01/2017
6	Neutropenia 01/2023 - 11/2013
5	Carcinoma (Carcinomatosis) 11/2023 - 07/2016
5	Microsatellite Instability 01/2023 - 12/2014
5	Squamous Cell Carcinoma (Epidermoid Carcinoma) 10/2022 - 11/2016
5	Infections 02/2021 - 06/2002
4	Squamous Cell Carcinoma of Head and Neck 09/2023 - 01/2022
3	Pneumonia (Pneumonitis) 12/2022 - 10/2011
3	Anorexia 10/2022 - 11/2013
3	Pancreatic Neoplasms (Pancreatic Cancer) 02/2021 - 01/2016
3	Interstitial Lung Diseases (Interstitial Lung Disease) 10/2018 - 02/2014
2	Drug-Related Side Effects and Adverse Reactions 02/2024 - 01/2017
2	Exanthema (Rash) 10/2022 - 01/2020
2	Hyponatremia 10/2022 - 01/2019
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2022 - 01/2022
2	Febrile Neutropenia 02/2021 - 01/2017
2	Leukopenia 01/2021 - 01/2019
2	Ascites 01/2020 - 04/2018
1	Esophageal Stenosis (Esophageal Stricture) 05/2023
1	Cholangiocarcinoma 01/2023
1	Gastrointestinal Neoplasms (Gastrointestinal Cancer) 01/2023
1	Biliary Tract Neoplasms (Biliary Tract Cancer) 01/2022

Drug/Important Bio-Agent (IBA)

16	Cisplatin (Platino)FDA LinkGeneric 01/2022 - 11/2013
15	Fluorouracil (Carac)FDA LinkGeneric 12/2022 - 11/2013
14	NivolumabIBA 02/2024 - 01/2017
12	pembrolizumabIBA 04/2024 - 01/2019
11	PlatinumIBA 04/2024 - 08/2013
11	Docetaxel (Taxotere)FDA Link 01/2024 - 11/2013
8	Paclitaxel (Taxol)FDA LinkGeneric 01/2024 - 01/2017
8	Cetuximab (Erbitux)FDA Link 08/2023 - 01/2018
7	Irinotecan (Camptosar)FDA LinkGeneric 08/2023 - 01/2020
6	trifluridine tipiracil drug combinationIBA 08/2023 - 11/2020
5	Immune Checkpoint InhibitorsIBA 05/2024 - 01/2020
5	Biomarkers (Surrogate Marker)IBA 01/2023 - 12/2014
5	Leucovorin (Folinic Acid)FDA Link 11/2021 - 04/2018
5	Oxaliplatin (Eloxatin)FDA LinkGeneric 08/2021 - 01/2020
4	taxaneIBA 04/2024 - 01/2017
4	regorafenibIBA 02/2024 - 01/2020
4	B7-H1 AntigenIBA 09/2023 - 01/2021
4	human ERBB2 proteinIBA 06/2022 - 08/2017
4	Trastuzumab (Herceptin)FDA Link 01/2022 - 08/2013
3	RamucirumabIBA 08/2023 - 07/2020
3	Taxoids (Taxanes)IBA 06/2023 - 03/2021
3	ErbB Receptors (EGF Receptor)IBA 01/2022 - 08/2013
3	Monoclonal AntibodiesIBA 01/2022 - 01/2019
3	130-nm albumin-bound paclitaxelIBA 08/2021 - 01/2017
3	Gemcitabine FDA Link 02/2021 - 01/2016
3	Alanine Transaminase (SGPT)IBA 01/2020 - 10/2011
2	tislelizumabIBA 01/2024 - 10/2022
2	Bevacizumab (Avastin)FDA Link 01/2023 - 01/2022
2	Programmed Cell Death 1 ReceptorIBA 10/2022 - 01/2021
2	Proteins (Proteins, Gene)FDA Link 06/2022 - 01/2021
2	AntibodiesIBA 01/2022 - 06/2002
2	Platinum Compounds (Compounds, Platinum)IBA 01/2022 - 07/2020
2	Circulating Tumor DNAIBA 01/2022 - 10/2021
2	HLA Antigens (Human Leukocyte Antigens)IBA 05/2020 - 04/2020
2	Everolimus FDA Link 01/2020 - 02/2014
2	CreatinineIBA 10/2018 - 01/2017
1	3-amino-1-methyl-3-(4-(3-phenyl-5H- imidazo(1,2- c)pyrido(3,4- e)(1,3)oxazin- 2- yl)phenyl)cyclobutanolIBA 02/2024
1	1-(2-(dodecyloxy)ethyl)pyrrolidine hydrochloride (DEP)IBA 02/2024
1	TAS-116IBA 02/2024
1	RNA (Ribonucleic Acid)IBA 02/2024
1	eribulin FDA Link 01/2024
1	Tumor Biomarkers (Tumor Markers)IBA 01/2024
1	encorafenibIBA 08/2023
1	binimetinibIBA 08/2023
1	pemigatinibIBA 01/2023
1	Trifluridine (Viroptic)FDA LinkGeneric 01/2023
1	NVP-BKM120IBA 10/2022
1	Notch ReceptorsIBA 10/2022
1	Type 2 Fibroblast Growth Factor Receptor (Fibroblast Growth Factor Receptor 2)IBA 06/2022
1	ParaffinIBA 01/2022
1	Hematoxylin (Haematoxylon)IBA 01/2022
1	durvalumabIBA 01/2022
1	CTLA-4 AntigenIBA 01/2022
1	Formaldehyde (Formol)FDA Link 01/2022
1	tremelimumabIBA 01/2022
1	lenvatinibIBA 01/2022
1	Eosine Yellowish-(YS) (Eosin)IBA 01/2022
1	pevonedistatIBA 08/2021
1	Capecitabine (Xeloda)FDA Link 08/2021

Therapy/Procedure

51	Drug Therapy (Chemotherapy) 04/2024 - 09/2008
24	Therapeutics 01/2024 - 02/2014
9	Chemoradiotherapy 11/2022 - 07/2016
6	Induction Chemotherapy 02/2021 - 07/2016
4	Adjuvant Chemotherapy 01/2019 - 12/2014
3	Neoadjuvant Therapy 05/2024 - 09/2008
3	Immunotherapy 02/2024 - 04/2020
3	Radiotherapy 01/2019 - 11/2015
2	Salvage Therapy 11/2022 - 10/2020
1	Endoscopes 05/2023
1	Molecular Targeted Therapy 01/2022
1	Precision Medicine 01/2022